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background: The aim of the study was to investigate 3-year major clinical outcomes in patients (pts) with different type of lesions treated 
with the zotarolimus-eluting stent (ZES) and everolimus-eluting stent (EES) in a series of Korean population in real-world clinical practice.
methods: A total of 1477 consecutive pts who underwent percutaneous coronary intervention (PCI) with ZES or SES from April 2003 
to July 2011 were enrolled. We analyzed the overall 3-year clinical outcomes with logistic regression, and according to left main lesion, 
bifurcation, small vessel lesion (<2.25mm), calcification, ostial lesion and diffuse long lesion (>3cm) after propensity score matching. 
Further, subgroup analysis was performed for diabetics.
results:  In overall study population after the baseline adjustment, there were no difference between two groups, with regard to total death 
(EES vs. ZES, OR 0.932, 95%CI 0.432-2.009, p=0.857) and cardiac death (OR 0.800, 95% CI 0.314-2.042, p=0.641), for myocardial 
infarction (OR 1.426, 95%CI 0.662-3.076, p=0.365), repeated revascularization (OR 0.992, 95% CI 0.667-1.474, p=0.967), and stent 
thrombosis (OR 1.212, 95%CI 0.400-3.671, p=0.734). However, in diabetic subgroup analysis, there was significant reduction of repeated 
revascularization in EES versus ZES (OR 0.474, 95% CI 0.232-0.971, p=0.041), and in bifurcation lesion (OR 0.245, 95%CI 0.070-0.865, 
p=0.029), and in calcified lesion (OR 0.211, 95%CI 0.054-0.834, p=0.026). There were no significant differences in total death, cardiac 
death, MI, and stent thrombosis between EES and ZES in diabetics.
Conclusion:  ZES and EES showed similar safety and efficacy during 3-year follow-up in patients with different type of lesions in all comer 
bases. However, in diabetic patients, EES was associated with lower incidence of repeated revascularization rate compared to ZES, 
especially in patients with bifurcation or calcified lesions.
